Featured Channels
Subscription preferences
O'Reilly Media
Strata Rx
-
1
8:44
When Data Disrupts Health Care
by OreillyMedia 5,240 views
O'Reilly Strata Rx Conference:
Leverage the Power of Big Data in Healthcare
Data is driving change in the healthcare industry. In the hands of those who know how to use it, data brings advances in personalized and predictive medicine, significant cost savings, and research that points to entirely new products and markets. If you want to leverage the power of big data for your organization, you don't want to miss the O'Reilly Strata Rx Conference. -
2
15:56
Strata Rx 2012: "The Convergence of Genomic and Phenomic Data", Alexis Borisy
by OreillyMedia 427 views
Personalized medicine, leading to better and more efficient medicine for many, will advance substantially as datasets combining broad genomic and other molecular data are combined with phenomic data -- rich clinical parameter datasets containing information that clinical decision makers really want to know. Although much attention has been paid to the genomic data, the phenomic data is often the greater challenge. Now progress is being made on both fronts, and these genomic-phenomic datasets have the potential for tremendous innovation in Rx, Dx, and more. Where are these joined datasets emerging from first? What opportunities for innovation do they provide? What may this mean for the future of the personalized medicine ecosystem?
Alexis Borisy
Third Rock Ventures
Alexis Borisy is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Mr. Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation of new companies. He co-founded Foundation Medicine and served as the company's first CEO and currently as its Chairman, co-founded Blueprint Medicines, and launched and is serving as interim CEO of Warp Drive Bio. Prior to joining Third Rock Ventures, Mr. Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised more than $1b in financing and business development deals, and has authored numerous scientific papers and patents.
Mr. Borisy was honored as the Massachusetts Institute of Technology's Technology Review Innovator of the Year, was chosen as the New England Entrepreneur of the Year in Life Sciences, and was honored as a Presidential Scholar. Mr. Borisy's undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work at Harvard University. -
3
5:48
Strata Rx 2012: "Opening Welcome", Julie Steele and Colin Hill
by OreillyMedia 279 views
Opening remarks by Strata Rx program chairs, Julie Steele (O'Reilly Media, Inc.) and Colin Hill (GNS Healthcare).
Julie Steele
O'Reilly Media, Inc.
Julie Steele is an editor at O'Reilly Media interested in connecting people and ideas. She finds beauty in discovering new ways to understand complex systems, and so enjoys topics related to gathering, storing, analyzing, and visualizing data. She holds a Master's degree in Political Science (International Relations) from Rutgers University.
Julie also works with topics related to the languages Python, PHP and SQL, and is co-founder of a group of non-programmers learning Python. Julie lives in NYC where she eats, reads, codes, and practices yoga.
Colin Hill
GNS Healthcare
Colin is a frequent speaker at international scientific and industry conferences and has appeared in numerous publications and television segments including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist. He serves as CEO and Chairman of GNS Healthcare's parent company Via Science, and chairman of the board of Fina Technologies, a subsidiary of Via Science that applies next-generation artificial intelligence technology to real-time financial trading. He also serves on the board of directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease.
In 2004, Colin was named to MIT Technology Review's TR100 list of the top innovators in the world under the age of 35. He graduated from Virginia Tech with a degree in physics and earned master's degrees in physics from McGill University and Cornell University. -
4
16:54
Strata Rx 2012: "Solving the Wanamaker Problem for Healthcare", Tim O'Reilly
by OreillyMedia 459 views
In the early days of the 20th century, department store magnate John Wanamaker famously said, "I know that half of my advertising doesn't work. The problem is that I don't know which half." The consumer internet revolution was fueled by the use of massive amounts of data to answer that problem. Now, the same transformation awaits in healthcare.
The opportunities are huge: for entrepreneurs and data scientists looking to put their skills to work disrupting a huge market, for researchers trying to make sense out of the flood of data they are now generating, and for existing companies (including health insurance companies, biotech, pharmaceutical, and medical device companies, hospitals and other care providers) that are looking to remake their businesses for the coming world of outcome-based payment models.
Tim O'Reilly
O'Reilly Media, Inc.
Tim O'Reilly is the founder and CEO of O'Reilly Media, Inc., thought by many to be the best computer book publisher in the world. O'Reilly Media also hosts conferences on technology topics, including the O'Reilly Open Source Convention, the Web 2.0 Summit, Strata: The Business of Data, and many others. O'Reilly's Make: magazine and Maker Faire has been compared to the West Coast Computer Faire, which launched the personal computer revolution. Tim's blog, O'Reilly Radar, "watches the alpha geeks" to determine emerging technology trends, and serves as a platform for advocacy about issues of importance to the technical community. Tim is also a partner at O'Reilly AlphaTech Ventures, O'Reilly's early stage venture firm, and is on the board of Safari Books Online. -
5
15:40
Strata Rx 2012: "Preparing for Surprise", Carol McCall
by OreillyMedia 361 views
Mark Twain once said "it ain't what you don't know that gets you into trouble. It's what you know for sure that just ain't so."
Knowing things 'for sure' is hard, especially in healthcare, as the WSJ noted in recent articles (one drawing attention to the irreproducibility of clinical trial results, calling it one of medicine's dirty secrets, and another critical of an increasingly common type of medical investigation, the observational study).
These are big, big issues. We want medicine to be scientific, because we believe that science works (and we want, with all our hearts, that which works). But as Kathryn Schulz points out, being wrong is hard, especially when it turns into an inflammatory statement (money and reputations are at stake, after all). And yet, as the WSJ points out, we often are.
To address the issues we face in healthcare we must be able to be wrong. We must quell our (false) certainties and, rather than "look for what we're looking for", allow ourselves to be surprised. How can we prepare to be surprised?
Big Data can help. By letting go of old paradigms that start by assuming only certain variables are key and end by correlating only these, we can stress-test all possible hypotheses and apply methods that give us more than correlation, which say that "A causes B", (rather than just "A and B are correlated"). After all, don't we really want to know, if we possibly can, what causes what?
Carol McCall
GNS Healthcare
Carol McCall is a health actuary with a background in innovation, predictive analytics and health services design. Her specialties are creating novel computational approaches that leverage 'big data' in healthcare, and designing services and business models that expand the traditional notions of health, care, community and sustainability.
Carol is the Chief Strategy Officer for GNS Healthcare, a Big Data Analytics company whose industrialized knowledge discovery platform extracts cause-effect relationships directly and at scale from observational data. Her personal goal is to leverage these capabilities to redesign the entire notion of 'evidence' and ignite a true learning system in the healthcare system.
Prior to joining GNS Healthcare, Carol was Chief Innovation Officer for Tenzing Health, a subsidiary of Vanguard Health Systems, where she merged creative analytic approaches with human-centered design. Building team-based care models whose approach extended into the community, these approaches were shown to materially improve health, dramatically reduce costs and open new opportunities in a community's economic sustainability.
At Humana, Carol led their R&D efforts in their Innovation Center where she pioneered using sophisticated analytics to build a diverse portfolio of prediction, knowledge discovery and simulation models. She also launched Humana's innovations in personalized medicine, led Humana's Health Services Research Center (HSRC), and helped launch Green Ribbon Health, LLC, a Florida-based company with innovations in health support services for seniors, later serving on its Board of Directors. In other roles at Humana, Carol served as their Chief Information Officer and as VP, Pharmacy Management.
Outside of Humana, she served as EVP of Managed Care Business Development for Allscripts Healthcare Solutions and as an actuarial consultant for Milliman, where she helped fashion novel risk-sharing arrangements and implement risk adjustment methodologies.
In policy and advisory roles, Carol served a four-year term as member of the nation's National Committee on Vital and Health Statistics, served as an advisor to the HRP Scientific Program Board, and was a member of the HSRC's governing board. She currently sits on the advisory board of Keas, a consumer health company.
Carol is a fellow of the Society of Actuaries and a member of the American Academy of Actuaries. -
6
12:51
Strata Rx 2012: "Own Your Data", Anne Wojcicki
by OreillyMedia 902 views
Anne Wojcicki
23andMe
Anne brings to 23andMe a 10-year background in healthcare investing, focused primarily on biotechnology companies. Anne left the investing world with the hope that she could have a positive impact on research and medicine through 23andMe. From her vantage point, Anne saw a need for creating a way to generate more information -- especially more personalized information -- so that commercial and academic researchers could better understand and develop new drugs and diagnostics. By encouraging individuals to access and learn about their own genetic information, 23andMe will create a common, standardized resource that has the potential to accelerate drug discovery and bring personalized medicine to the public. (Plus, getting access to her own genetic information and understanding it has always been one of Anne's ambitions.) Anne graduated from Yale University with a B.S. in biology. -
7
13:31
Strata Rx 2012: "Unleashing the Power of Medicare Data...", Niall Brennan
by OreillyMedia 349 views
Keynote by Niall Brennan, Director for the Policy and Data Analysis Group, Center for Strategic Planning at the Centers for Medicare and Medicaid Services.
Niall Brennan
Center for Strategic Planning, Centers for Medicare and Medicaid Services
Niall Brennan is the Director in the Policy and Data Analysis Group in the Center for Strategic Planning at the Centers for Medicare and Medicaid Services where he oversees a range of activities related to the overall strategic goals of the agency. The office performs a variety of analyses on high profile issues on a quick turnaround basis, to the CMS administrator, senior leaders and other HHS department leaders.
Prior to joining CMS, Brennan directed the Characterizing Episodes and Costs of Care (C3) project, a joint Brookings Institution/American Board of Medical Specialties initiative to develop a starter set of fully transparent, episode-based cost-of-care measures that is funded by the Robert Wood Johnson Foundation, conducted research related to comparisons of quality between the Medicare fee-for-service and Medicare Advantage programs and managed the activities of the workgroups of the Quality Alliance Steering Committee (QASC). Prior to joining Brookings, Brennan was a Senior Analyst at the Medicare Payment Advisory Commission where he directed studies on measuring physician quality and cost and the Medicare Advantage program. He was previously a principal analyst in the Budget Analysis Division at the Congressional Budget Office, where he worked on estimates related to Medicare reform, the Medicare drug benefit, and the Medicare hospital outpatient prospective payment system. Previously, Brennan worked as a research associate at The Urban Institute, where he focused on issues relating to health insurance coverage, Medicaid managed care, and safety net hospitals, and as a consultant in the Health Economics Group at Price Waterhouse.
He is a graduate of University College Dublin, and earned a master's degree in Public Policy from Georgetown University. -
8
16:01
Strata Rx 2012: "A Small Proposal: One Experiment", James Heywood
by OreillyMedia 563 views
What would happen if we measured health, disease, and it's impact in one connected network? A proposal to break down the silos and re-index research around the individual.
James Heywood
PatientsLikeMe
An MIT engineer, Jamie entered the field of translational research and medicine when his brother Stephen was diagnosed with ALS in 1998 at the age of 29. With experience in design, information technology, systems modeling, neuroscience and industrial engineering, Jamie brings a unique perspective to drug discovery and medicine. The scientific and business innovations he developed at ALS TDI and PatientsLikeMe have been transforming the intersection of biotechnology and pharmaceutical development, personalized medicine, and patient care.
Currently, Jamie serves as chairman of PatientsLikeMe, where he provides the scientific vision and architecture for its patient-centered medical platform. He co-founded the company in 2005 with his youngest brother, Benjamin, and friend, Jeff Cole. Named one of "15 companies that will change the world" by CNNMoney, PatientsLikeMe is a personalized research and peer care platform that allows patients to share in-depth information on treatments, symptoms and outcomes. This novel open model allows clinicians, providers, and the pharmaceutical industry to better understand diseases and the patient experience. Patients experience improved care and the ability to actively partner with industry to accelerate and influence the development of new treatments and biomarkers.
In 1999 shortly after Stephen was diagnosed, Jamie founded the ALS Therapy Development Institute (ALS TDI), the world's first non-profit biotechnology company, where he served as CEO until 2007. Pioneering an open research model and an industrialized therapeutic validation process, Jamie led ALS TDI to become the world's largest and most comprehensive ALS research program. The journal Nature captured succinctly the broader implications of ALS TDI's program, saying it succeeded in "prompting a broad reappraisal of the way that drugs are tested in animal models of neurodegenerative disease in general." The comprehensive in-vivo validation program Jamie developed was unable to replicate the published preclinical studies of the field that lead to human trials calling into question the standards that allowed many drugs to be tested on patients. Today, ALS TDI continues to grow and runs large-scale discovery and informatics program focused on finding an effective pathway for treating ALS.
Jamie is a frequent speaker, media pundit and an active investment advisor. His work has been profiled in the New Yorker, New York Times Magazine, BusinessWeek, 60 Minutes, Science, Nature as well as in Pulitzer Prize winner Jonathan Wiener's biography, His Brothers Keeper and the Sundance award-winning documentary, "So Much So Fast." -
9
5:18
Strata Rx 2012: "It's an Exciting Time in the Industry", Bill Schmarzo
by OreillyMedia 297 views
Big data is the next evolution in health sciences analytics. New and varied data sources combined with advances in technology are enabling innovative solutions that result in faster and more accurate insights for everything from claims processing to sales analysis to patient engagement to outbreak detection.
Bill Schmarzo
EMC Consulting
Bill Schmarzo has more than two decades of experience in data warehousing, BI and analytic applications. Bill authored the Business Benefits Analysis methodology that links an organization's strategic business initiatives with their supporting data and analytic requirements, and co-authored with Ralph Kimball a series of articles on analytic applications. Bill has served on The Data Warehouse Institute's faculty as the head of the analytic applications curriculum.
Previously, Bill was the vice president of Analytics at Yahoo where he was responsible for the development of Yahoo's Advertiser and Website analytics products, including the delivery of "actionable insights" through a holistic user experience. Before that, Bill oversaw the Analytic Applications business unit at Business Objects, including the development, marketing and sales of their industry-leading analytic applications.
Bill holds a masters degree in Business Administration from the University of Iowa and a bachelor of science degree in Mathematics, Computer Science and Business Administration from Coe College. -
10
16:02
Strata Rx 2012: "Keynote", Tina Brown-Stevenson
by OreillyMedia 369 views
Tina Brown-Stevenson
SVP, Healthcare Analytics & Decision Support, UnitedHealth Networks
Tina Brown-Stevenson is the Senior Vice President, Healthcare Analytics & Decision Support at UnitedHealthcare. In 2010, her contributions to health care earned her national recognition in the annual "Women Worth Watching" issue of Profiles in Diversity Journal, an issue dedicated to highlighting women leaders who make a difference.
Previously, Brown-Stevenson was the executive vice president of the Health Care Innovation and Information Group at OptumInsight. Before joining OptumInsight, Brown-Stevenson was president and head of Aetna Informatics, Aetna's data, information, and analytics subsidiary responsible for statistical modeling, plan sponsor reporting, data warehousing, and analytical product development. Prior to joining Aetna in 2001, Brown-Stevenson served as the vice president of HealthCare Economics at Cigna, as vice president of Health System Development at Partners Healthcare System in Boston, and as vice president for Medical Management of UnitedHealthcare's New England health plan.
Brown-Stevenson is a Certified Managed Care executive who received her MA in health administration from Framingham State College and her BS in nursing from the University of Massachusetts at Amherst. She has completed post-graduate work in health informatics, and is a frequent guest lecturer on managed care and applied health services research. Brown-Stevenson is a member of the board of trustees of the Connecticut Health Foundation, and a former board member of both the Aurora Foundation and the Aetna Foundation. -
11
15:37
Strata Rx 2012: "Dreaming of Tenure and IPOs While Patients Suffer...", Stephen Friend
by OreillyMedia 423 views
I wonder what it will take to transition biomedical research to a haven for rapid learning, networked team approaches, and sharing insights that have been powering up the software industry and enabled physicists for decades. I wonder what it will take for citizens to rise up and say the current reward structures in academia where the majority of the NIH/government grants (that's your money) is given to scientists who expect to not share their insights till submitted to journals, and current operation models for biotech where VCs patrol for breaches in secrecy around insights they have made about human diseases such as Parkinson''s using samples from patients till they can take out patents. We need to show how a world of open science, building off of each other's work can be rewarded, to show how challenges and open competitions lead to sharing.
Stephen Friend
Sage Bionetworks
Dr. Friend is the President of Sage Bionetworks. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the NCI, several biotech companies, a Trustee of the AACR and is a AAAS and Ashoka Fellow as well as an editorial board memeber of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck's Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center's Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University. -
12
7:47
Strata Rx 2012: "Buxton's Ghost: The Ethos of Healthcare Data Science", Fred Trotter
by OreillyMedia 885 views
What relationship do we, as data scientists, have with patients? The relationship between patient and doctor, when it changes to scientist and test subject has always been strained. Big Data in healthcare will only increase this strain, unless it is used to empower patients. This talk will cover the state of the art in using Big Data to empower patients including the efforts to open up government data sets as part of healthdata.gov. Most importantly, this talk will see the release of an entirely new healthcare data set: The Strata Rx mystery data set. The data set will available initially only to Strata Rx attendees.
Fred Trotter
FredTrotter.com
Fred Trotter is a hacktivist, coding for social change. Trotter is one of the most celebrated health IT and health IT security experts in the country. He is one of the designers of the Direct Project, which is now a mandated health information exchange protocol in the United States. He, along with David Uhlman, wrote the first Health IT book for O'Reilly and the most popular book on the Meaningful Use standards: Meaningful Use and Beyond. Fred is always looking for ways to use to technology to empower patients to get better healthcare. -
13
8:55
Support the Proposed Federal Rule to Expand the Rights of Patients to Access Their Test Results
by OreillyMedia 814 views
http://oreil.ly/patient-tests
Support the Proposed Federal Rule to Expand the Rights of Patients to Access Their Test Results
Tim O'Reilly asks you to join him in improving patients' rights. By adding your signature to the letter below, you can voice your support for a proposed federal rule that expands patients' access to test results. "I'm convinced that there's a wave of innovation coming in healthcare, driven by new kinds of data, new ways of extracting meaning from that data, and new business models that data can enable," Tim says. While much of that data is still unavailable, efforts such as this consensus letter advance the progress of open data in healthcare. The letter asks the federal government to finalize a proposed rule that gives patients those rights. If you agree, sign the letter. A summary of the letter's main points is below.
Summary of Letter Supporting the Proposed Federal Rule to Expand the Rights of Patients to Access Their Test Results
Patients need quick, convenient access to their medical records in order to better manage their health. Patients' rights should include direct access to their lab results, just like all their other medical records.
In 2011, HHS put forward a proposed Rule that would give patients the right to get their test results directly from laboratories. Today, due to the interaction of HIPAA (the federal medical privacy law, CLIA (a federal laboratory regulatory law), and state laws, patients can only get direct access to their their test results from labs in a handful of states. The proposed Rule would give patients that right in all 50 states. This consensus letter voices our whole-hearted support for that proposed Rule and encourages the federal government to finalize it promptly.
A 2009 law modernized patient access rights by allowing individuals to get copies of their medical records in electronic format. Unfortunately, however, patients' access rights do not include lab test results. Lab test results are in a uniquely restricted category compared to other health information, which impairs patients' ability to see, save, use, and share their own test results.
Our position. Our reasons for supporting the proposed Rule include:
Providing direct and timely access to test results will improve patient care.
Preventing patients from accessing their own lab results impedes the successful development of emerging health care technologies, since many innovative and useful tools rely upon the patient's access to their own health data.
Many patients need to pass along their results to another provider, yet patients can only deliver what they possess. Time is valuable and having a copy on hand will help patients during medical emergencies.
Providing direct access to lab results will decrease health care costs. As Todd Park, the federal Chief Technology Officer, said, "When patients have timely access to their records, they can spot errors and omissions, which improves treatment outcomes and helps them avoid unnecessary procedures."
Improving patient engagement is a crucial national priority, and giving patients direct access to lab results will help them actively participate in their care. -
14
22:15
Strata Rx 2012: "A Conversation with Vinod Khosla", Tim O'Reilly & Vinod Khosla
by OreillyMedia 1,397 views
Tim O'Reilly in conversation with Vinod Khosla, Founder of Khosla Ventures.
Tim O'Reilly
O'Reilly Media, Inc.
Tim O'Reilly is the founder and CEO of O'Reilly Media, Inc., thought by many to be the best computer book publisher in the world. O'Reilly Media also hosts conferences on technology topics, including the O'Reilly Open Source Convention, the Web 2.0 Summit, Strata: The Business of Data, and many others. O'Reilly's Make: magazine and Maker Faire has been compared to the West Coast Computer Faire, which launched the personal computer revolution. Tim's blog, O'Reilly Radar, "watches the alpha geeks" to determine emerging technology trends, and serves as a platform for advocacy about issues of importance to the technical community. Tim is also a partner at O'Reilly AlphaTech Ventures, O'Reilly's early stage venture firm, and is on the board of Safari Books Online.
Vinod Khosla
Khosla Ventures
Vinod Khosla is an entrepreneur, investor, and technology fan. He is the founder of Khosla Ventures, focused on impactful clean technology and information technology investments. Mr. Khosla was a co-founder of Daisy systems and founding CEO of Sun Microsystems where he pioneered open systems and commercial RISC processors. One of Mr. Khosla's greatest passions is being a mentor to entrepreneurs, assisting entrepreneurs and helping them build technology based businesses. Mr. Khosla is driven by the desire to make positive impact through scaling alternative energy, achieving petroleum independence, and promoting a pragmatic approach to the environment. He is also passionate about Social Entrepreneurship. Vinod holds a Bachelor of Technology in Electrical Engineering from IIT, New Delhi, a Master's in Biomedical Engineering from Carnegie Mellon University and an MBA from the Stanford Graduate School of Business. -
15
3:44
Strata Rx 2012: "Support the Proposed Federal Rule to...", Ann B. Waldo
by OreillyMedia 101 views
Ann Waldo
Wittie, Letsche & Waldo, LLP
Ms. Waldo's law practice is focused on privacy, information security and health care issues. She is experienced in advising clients regarding privacy compliance, risk management, information security, marketing, international data transfers, and integrating privacy goals into business strategies. She counsels and represents clients regarding public policy, external relations, and government relations matters in the fields of privacy and health care.
Ms. Waldo served as an in-house lawyer for much of her career. She was the global Chief Privacy Officer for Lenovo, a large international computer manufacturer, where she was responsible for compliance with privacy laws applicable to marketing, human resources, international data transfers, and product development. She also represented the company's public policy positions in domestic and international privacy conferences and negotiations. She previously led privacy compliance as Chief Privacy Officer for Hoffmann-La Roche, a large international pharmaceutical company, and worked in public policy for GlaxoSmithKline, providing legislative support on privacy and other matters. She was actively involved with the International Pharmaceutical Privacy Consortium. She served as in-house counsel at IBM, working on consumer protection, marketing, and e-business. Prior to her work at IBM, she had been a commercial litigator and had handled tax legislation for a state legislature.
She counsels clients on consumer-law privacy matters, which apply to businesses in general, as well as privacy laws specific to the health care sector (HIPAA and HITECH). She has particular interest in and experience with emerging technologies that handle sensitive health information, such as personal health records, genetics-related companies, and Health Information Exchanges. She has served on the Personal Health Record work group for the Certification Commission on Health Information Technology, has advised a state Health Information Exchange, and currently serves on the Board of Advisors for the Harvard SHARP grant on substitutable electronic health record components.
A frequent public speaker, Ms. Waldo is active in the International Association of Privacy Professionals and the Carolina Privacy Officials Network, has consulted with foreign governments regarding privacy laws, and has represented the United States government in APEC privacy talks in Korea and Australia. She is a Certified Information Privacy Professional. -
16
15:38
Strata Rx 2012: "Choose Your Monopolies Wisely", John Wilbanks
by OreillyMedia 566 views
Many of the biggest impacts of technology have been driven by monopolies and their network effects. The question is what kind of monopoly we choose, and what impacts our choices create. When we choose open standards as our monopolies, we get vast open networks -- HTML, TCP/IP, and other systems where anyone can compete. When we choose walled gardens as our monopolies, we get a very different results -- Apple, Facebook, and Twitter control precisely how and when competition and entrepreneurship can happen. We're faced with this choice right now, and the decisions we make will define the next twenty years of technology in health.
John Wilbanks
Kauffman Foundation for Entrepreneurship
John Wilbanks works on open content, open data, and open innovation systems. He is a Senior Fellow at the Kauffman Foundation and a Research Fellow at Lybba. He's worked at Harvard Law School, MIT's Computer Science and Artificial Intelligence Laboratory, the World Wide Web Consortium, the US House of Representatives, and Creative Commons, as well as starting a bioinformatics company. He sits on the Board of Directors for Sage Bionetworks, iCommons, and 1DegreeBio, and the Advisory Board for Boundless Learning. John holds a degree in philosophy from Tulane University and also studied modern letters at the University of Paris (La Sorbonne). -
17
9:29
Strata Rx 2012: "Real World Evidence Meets Big Data: ...", Andrew Kress
by OreillyMedia 282 views
Keynote by Andrew Kress, Senior Vice President, Healthcare Value Solutions for IMS Health.
Andrew Kress
IMS Health
Andrew Kress is senior vice president, Healthcare Value Solutions for IMS Health. In this role, he leads IMS initiatives that connect healthcare stakeholders through real-world evidence to demonstrate the value of medicines, enhance quality and drive improved outcomes. Andrew is responsible for a portfolio of growth platforms, including IMS's Health Economics and Outcomes Research, Clinical Trial Optimization Services, Government Solutions and, Payer and Provider Solutions businesses.
Andrew joined IMS in 2011 with the acquisition of SDI Health, a leading U.S.-based healthcare market insights and analytics firm, where he served as president and CEO since 2006. In this role, Andrew led the company's expansion from primary market research into the longitudinal patient-level data space, guided product development activities and advanced relationships with key data suppliers.
Prior to this appointment, he held roles of increasing responsibility with SDI, including president from 1998 to 2006 and, from 1992 to 1998, vice president responsible for sales to pharmaceutical and consumer products clients in the U.S. and other markets. He joined the organization in 1991.
Andrew holds a B.A. degree from Yale University. -
18
14:35
Strata 2012: "Knowledge Sharing and Personalized Clinical...", Blackford Middleton
by OreillyMedia 222 views
In this talk Dr. Middleton will share his vision of a learning healthcare delivery system enabled by knowledge and data sharing, discovery and feedback, and effective personalized clinical decision support offered to providers and patients. Key lessons learned and examples will be drawn from research and development at Partners Healthcare and Harvard Medical School.
Blackford Middleton
Partners Healthcare System
Blackford Middleton is Corporate Director of Clinical Informatics Research & Development (CIRD) at Partners Healthcare System, Boston, and Assistant Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, and a Lecturer in Health Policy and Management at the Harvard School of Public Health. He is adjunct faculty at the Technische Universität München, Graduate School of Information Science in Health, Munich, Germany, and the Clinical Excellence Research Center at Stanford University.
As Corporate Director for CIRD, he leads the groups responsible for developing Partners enterprise clinical informatics infrastructure development, software product design for the Partners EMR and patient portal, enterprise clinical decision support and knowledge management services, and conducts clinical informatics research. In 2004 CIRD joined the National Library of Medicine sponsored Boston-area Informatics Research and Training Fellowship Program, where Dr. Middleton serves as Fellowship Program Director for CIRD Fellows.
Dr. Middleton was appointed by US Secretary of Health and Human Services Michael Leavitt to serve on the National Committee of Vital and Health Statistics (NCHVS) in 2008, and serves on the Quality, and Population NCVHS sub-committees. Currently, he is a member of the National Quality Forum Health IT Advisory Council, the Board of Directors at the American Medical Informatics Association (AMIA), and serves on the National Advisory Committee of the Robert Wood Johnson Foundation Aligning Forces for Quality program (Dr. Mark McClellan, Chair). He also serves on the Board of Stewardship Trustees for the Catholic Health Initiatives (CHI) health system (and Quality, and Strategy sub-committees of the Board), the Board of Directors of the CHI Institute for Research and Innovation, the Medical Knowledge Institute, and several Editorial Boards. He was a co-founder of the Institute for Decision Systems Research in Palo Alto, CA in 1994, and of the Center for Information Technology Leadership (C!TL) at Partners in 2002 and led its research in value-based technology assessment until 2010. He is past Treasurer of the American Telemedicine Association, and the American College of Medical Informatics, and past Chairman of the Computer-based Patient Record Institute (CPRI, 2000), and Chairman of the Healthcare Information Management & Systems Society (HIMSS, 2005).
Dr. Middleton was recognized by Modern Healthcare as one of the US Top 25 Clinical Informaticists in 2010. Dr. Middleton received the SUNY-Buffalo Medical Alumni Achievement Award -- "Presented in honor of your extraordinary accomplishments and leadership in the field of medicine" in 2010. He was recognized in 2011 as one of HIMSS 50 in 50: 50 individuals who "have made recognized, lasting, and influential contributions to the theory, adoption, and use of healthcare information and management systems" in HIMSS 50 year history. Dr. Middleton is a Fellow of the American College of Physicians, the American College of Medical Informatics, and of HIMSS.
Dr. Middleton studied Biochemistry and Molecular at the University of Colorado, Boulder. He received a Masters in Public Health degree from the Yale University School of Public Health with a dual concentration in Epidemiology, and Health Services Administration. He received an MD from SUNY Buffalo, and was a resident in internal medicine at the University of Connecticut Health Sciences Center. He completed an AHCPR Fellowship in General Internal Medicine at Stanford University, where he received his Master of Science degree in Health Services Research, focusing on clinical informatics. -
19
14:41
Stata Rx 2012: "Bigger Data or Better Questions?", Alexandra Drane
by OreillyMedia 500 views
Historically, the health care space has done a whole lot of 'talking at' and 'lecturing to' and not a whole lot of listening -- to what really matters, to what really resonates -- and not just to those who offer up their opinions, but perhaps even more importantly...to the millions of nameless faceless individuals out there struggling with where real life meets their health. Now the healthcare space is sitting on a mess of data -- actual data reflecting how real people live and think and interact with the world around them. It's time to pore through the data...to listen really hard...to focus on separating signal from noise -- looking for what is really there as opposed to what we think should be there. Is engagement data more telling than claims data? Is vulnerability more important than risk? Can we open our minds and our warehouses to consider these questions? Is it bigger data we need? Or is it higher fidelity, more relevant data that's missing... And remember -- knowing something is different than doing something -- so the next question becomes: Once you've tamed your big data, what are you going to do with what you learned?
Alexandra Drane
Eliza Corporation
Alexandra sets the vision and strategy for Eliza, and is responsible for maintaining Eliza's leadership position in the healthcare industry. She has devoted her career to inspiring people to lead healthier, happier and more engaged lives through the use of innovative technology, and her entrepreneurial spirit and passion for technology and design have led to the launch of four successful healthcare ventures over the past 15 years. Alexandra has proven herself a visionary and an innovator, whose ideas on using technology to engage people in their health -- and her belief in adding a touch of joy to the often staid world of healthcare communications -- have been adopted by the nation's top healthcare organizations.
Alexandra is currently Founder, Chief Visionary Officer, and Chairman of the Board of Eliza Corporation, the pioneer and leader in Health Engagement Management and one of Entrepreneur magazine's "100 Brilliant Companies." The company's intelligent, tailored interactions—including automated calls powered by a patented speech recognition engine, rich web and multi-modal delivery platform and proprietary sophisticated data analytics—make health and healthcare information more accessible, more actionable and more engaging.
Eliza draws on its database of more than 700 million interactions with individuals about their health to better understand what makes people "tick" and create programs with measurable and sustained impact. Examples include increasing the number of patients who get their recommended diabetes screenings by 76%; more than doubling prescription refills over a six-month period; quadrupling participation in an online smoking cessation program; and boosting younger members' perceptions of their health plans' brands beyond what far more expensive traditional advertising campaigns deliver. But perhaps most important are the countless saved lives as the result of timely, personalized health outreach. Alexandra is also a co-founder of Engage with Grace, a not-for-profit movement launched in October 2008 aimed at helping people understand, communicate and have honored their end-of-life wishes. She received the Boston Business Journal's "Champions of Healthcare" award for her efforts in this area, and Engage With Grace has been added to the healthcare lexicon as a top ten phrase.
Based on her experience engaging people in conversation about health topics, in 2010 she co-founded a non-profit, web-based movement called SeduceHealth that aims to reframe how the healthcare industry communicates with the people it serves by adding greater passion, joy, and inspiration.
Prior to founding Eliza, Alexandra was a founder of three other healthcare ventures -- all focused on developing products that enable individual behavior change through the use of technology. The output of these ventures included the web-enabled injury-tracking software system adopted by the US Olympic Committee, software that automates dialysis clinics across the U.S., and a medical device proven in clinical trials to improve asthma treatment compliance by over 35%.
Alexandra sits on the board of Eliza, the Board of Trustees for Beth Israel Deaconess Medical Center (a Harvard Teaching Hospital) in Boston, MA, the Board of Advisors of TEDMED, and the Harvard Executive Sleep Council. She also sits on the Board of Directors and the Operations Committee of the Coalition to Transform Advanced Care (C-TAC) and co-chairs C-TAC's Public Engagement Workgroup. Alexandra is a member of the Health Executive Leadership Network, Women Business Leaders of the U.S. Health Care Industry Foundation, and is a trustee of several charitable trusts. -
20
28:40
The Emergence of Proactive P4 Medicine: A Revolution in Healthcare - Leroy Hood
by OreillyMedia 483 views
Dr. Leroy Hood with the Institute of Systems Biology will focus on their efforts at taking a systems approach to diseases—looking at a neurodegenerative (prion) disease, PTSD and a brain tumor (glioblastoma) in mice and humans. The mouse models allows them to analyze the initiation and progression of these diseases dynamically—enabling them to building models that reflect the pathophysiology of the disease. They have also taken a systems approach to blood diagnostics and have generated powerful diagnostic markers for the first two of these diseases.
He will then discuss the emerging technologies that will transform biology and medicine over the next 10 years—e.g., next generation DNA sequencing and its applications to human genome sequencing, targeted mass spectrometry, microfluidic protein chips, new approaches to protein-capture agents, single-cell analyses and the use of induced pluripotential (iPS) cells to enlighten our understand of development, disease mechanisms and disease stratification.
Three converging opportunities—systems medicine, big data and patient-activated social networks—will lead to a proactive P4 medicine that is predictive, personalized, preventive and participatory (P4). Dr. Hood will describe the nature of P4 medicine and its societal implications for healthcare, and briefly mention some of the strategic partnerships that the Institute of Systems Biology has developed to bring P4 medicine to patients.
Leroy Hood
Institute for Systems Biology
Dr. Hood is a pioneer in the systems approach to biology and medicine. His research has focused on the study of molecular immunology, biotechnology and genomics. Dr. Hood's professional career began at Caltech, where he and his colleagues developed the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer----four instruments that paved the way for the successful mapping of the human genome. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, The Accelerator and Integrated Diagnostics. He is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. Of the 6,000+ scientists world-wide who belong to one or more of these academies, Dr. Hood is one of only fifteen people accepted to all three. He is also a member of the American Philosophical Society and a Fellow of the American Academy of Arts and Sciences. His work has been widely published, and he has coauthored numerous textbooks in biochemistry, immunology, molecular biology and genetics, as well as a popular book on the human genome project, The Code of Codes. He is the recipient of numerous awards, including the Lasker Award for Studies of Immune Diversity, the Kyoto Prize in advanced technology, the Heinz Award for pioneering work in Systems Biology, and most recently, the coveted NAE 2011 Fritz J. and Delores H. Russ Prize for automating DNA sequencing that revolutionized biomedicine and forensic science. In addition to having received 17 honorary degrees from prestigious universities in the US and abroad, Dr. Hood has published more than 700 peer reviewed articles and currently holds 36 patents. -
22
10:26
Khaled El Emam interviewed at Strata Rx
by OreillyMedia 297 views
Khaled El Emam
Canada Research Chair in Electronic Health Information, Children's Hospital of Eastern Ontario - Research Institute & University of Ottawa
Dr. Khaled El Emam is an Associate Professor at the University of Ottawa, Faculty of Medicine, a senior investigator at the Children's Hospital of Eastern Ontario Research Institute, and a Canada Research Chair in Electronic Health Information at the University of Ottawa. His main area of research is developing techniques for health data de-identification or anonymization and secure disease surveillance for public health purposes. Previously Khaled was a Senior Research Officer at the National Research Council of Canada, and prior to that he was head of the Quantitative Methods Group at the Fraunhofer Institute in Kaiserslautern, Germany. He has co-founded two companies to commercialize the results of his research work. In 2003 and 2004, he was ranked as the top systems and software engineering scholar worldwide by the Journal of Systems and Software based on his research on measurement and quality evaluation and improvement, and ranked second in 2002 and 2005. He holds a Ph.D. from the Department of Electrical and Electronics, King's College, at the University of London (UK). His website is www.ehealthinformation.ca He is very influential and a thought leader in the privacy and health information space. In addition, he is one of only a handful of individuals known worldwide to be qualified to de-identify personal health information. -
23
20:53
Strata RX 2012- Ajay Verna Keynote - Wednesday 10/17/12
by OreillyMedia 263 views
Neurologic diseases include more than 600 conditions, affect approximately one billion people worldwide, and are rising rapidly with aging populations. Unlike other organ systems, where the emergence of normative biomarkers such as blood pressure and cholesterol numbers has greatly improved health management, personalized metrics for fundamental brain functions are lacking. Although the complexity of human brains and the diversity of our behavioral traits has made this a daunting task in the past, advancements in technology and information sciences now promise near-term breakthroughs. This presentation highlights new opportunities for using large neurometric datasets to develop personalized medicine approaches for improving brain health and developing therapeutics.
Ajay Verma
Biogen Idec
Ajay Verma studied zoology at the University of Maryland and received his MD and PhD from The Johns Hopkins University. His neuroscience training was in the laboratory of Dr. Soloman Snyder. His neurology training was at the Walter Reed Army Medical Center where he was a staff Neurologist for 11 years. He was also a tenured Professor in Neurology, and Neuroscience at the Uniformed Service University of the Health Sciences, the US Military's Medical School. Since leaving the Army as a Lt. Colonel in 2006, Ajay has worked at Merck & Co., Inc. and Novartis Pharmaceuticals. He is currently Global Vice President at Biogen Idec for Neurology and Experimental Medicine. -
24
13:49
Strata RX 2012 - David Ewing Duncan Keynote - Wednesday 10/17/12
by OreillyMedia 123 views
Keynote by David Ewing Duncan, award-winning, best-selling author of eight books, journalist and a television, radio and film producer and correspondent.
David Ewing Duncan
.
David Ewing Duncan is an award-winning, best-selling author of eight books published in 19 languages; he is a journalist and a television, radio and film producer and correspondent. His most recent book is When I'm 164: The new science of radical life extension, and what happens if it succeeds(TED Books). He is a Correspondent for The Atlantic, and the Chief Correspondent of public radio's Biotech Nation, heard on NPR Talk. David writes for The New York Times, Fortune , Wired, National Geographic, Discover, Atlantic Monthly, and many other publications. He is the Founding Director of the Center of Life Science Policy at UC Berkeley, and the Director of the Personalized Health Project. He has been a commentator on NPR's Morning Edition, and a contributing editor for Wired, Discover and Conde Nast Portfolio. He is a former special correspondent and producer for ABC Nightline and a correspondent for NOVA's ScienceNOW! His previous book was Experimental Man: What one man's body tells him about his future, your health, and our toxic world. David has won numerous awards including the Magazine Story of the Year from the American Association for the Advancement of Science. His articles have twice been cited in nominations for National Magazine Awards, and his work has appeared twice in The Best American Science and Nature Writing. David lives in San Francisco. -
25
13:35
Strata RX 2012 - Eric Schadt Keynote - Wednesday 10/17/1
by OreillyMedia 345 views
Integrating large-scale, high-dimensional molecular and physiological data holds promise in not only defining the molecular networks that directly respond to genetic and environmental perturbations that associate with disease, but in causally associating such networks with the physiological states associated with disease. Eric Schadt will discuss modeling approaches that integrate diverse types of data on broad scales to derive predictive network models that inform decision making on multiple levels, whether deciding on the next set of genes to validate experimentally or the best treatment for a given individual given detailed molecular and higher order data on their condition.
Eric Schadt
Mount Sinai School of Medicine
Dr. Eric Schadt recently joined Mount Sinai Medical School as Chairman and Professor, Department of Genetics and Genomic Sciences and as Director, Institute of Genomics and Multiscale Biology in 2011. Previously, Dr. Schadt had been the Chief Scientific Officer at Pacific Biosciences, overseeing the scientific strategy for the company, including creating the vision for next-generation sequencing applications of the company's technology. Dr. Schadt is also a founding member of Sage Bionetworks, an open access genomics initiative designed to build and support databases and an accessible platform for creating innovative, dynamic models of disease. Dr. Schadt's current efforts at Mount Sinai to generate and integrate large-scale, high-dimension molecular, cellular, and clinical data to build more predictive models of disease so that we may better diagnose and treat disease, were motivated by the genomics and systems biology research he led at Merck to elucidate common human diseases and drug response using novel computational approaches applied to genetic and molecular profiling data. His research helped revolutionize a field in statistical genetics (the genetics of gene expression), has energized the systems biology field, and has led to a number of discoveries relating to the causes of common human diseases. At the time Dr. Schadt left Merck in 2009, greater than 50% of all new drug discovery programs at Merck in the metabolic space were derived from Dr. Schadt's work. Dr. Schadt was also recently appointed as Fellow to the Institute of Systems and Synthetic Biology, Imperial College London. Dr. Schadt received his B.S. in applied mathematics/computer science from California Polytechnic State University, his M.A. in pure mathematics from UCD, and his Ph.D. in bio-mathematics from UCLA (requiring Ph.D. candidacy in molecular biology and mathematics). -
26
5:44
Nelli Lähteenmäki interviewed at Strata Rx
by OreillyMedia 464 views
Nelli Lähteenmäki ( Health Puzzle)
-
29
3:03
Brad Ryan interviewed at Strata Rx
by OreillyMedia 104 views
Brad Ryan, M.D.
General Manager, Payer and Provider Solutions, IMS Health
With many years of experience in Healthcare, including practicing medicine, Brad Ryan has a unique perspective on the future of healthcare. Currently, he is responsible for IMS solutions offered to healthcare payers and providers worldwide.
Brad joined IMS in February 2012. Prior to that, he worked at McKinsey & Company, where he served as a leader in the Pharmaceuticals and Medical Products Practice since 2005, driving strategy and growth engagements for clients across the healthcare value chain.
Brad has a notably broad view of industry issues from multiple angles, having worked with major provider, pharma, retail pharmacy, medical products, and health technology organizations on a variety of commercial, development, and productivity initiatives. He is an industry thought leader on a diverse range of healthcare topics, and applies that knowledge to create innovative analytics and knowledge-based technology solutions at IMS.
Brad started his career as a physician with the Department of General Surgery, University of Alabama -- Birmingham.
Brad holds a B.S. degree in Chemical Engineering from the University of Alabama, and an M.D. degree from Johns Hopkins University School of Medicine. -
30
1:59
Bill Schmarzo interviewed at Strata Rx
by OreillyMedia 72 views
Bill Schmarzo
CTO, EMC Consulting
Bill Schmarzo has more than two decades of experience in data warehousing, BI and analytic applications. Bill authored the Business Benefits Analysis methodology that links an organization's strategic business initiatives with their supporting data and analytic requirements, and co-authored with Ralph Kimball a series of articles on analytic applications. Bill has served on The Data Warehouse Institute's faculty as the head of the analytic applications curriculum.
Previously, Bill was the vice president of Analytics at Yahoo where he was responsible for the development of Yahoo's Advertiser and Website analytics products, including the delivery of "actionable insights" through a holistic user experience. Before that, Bill oversaw the Analytic Applications business unit at Business Objects, including the development, marketing and sales of their industry-leading analytic applications.
Bill holds a masters degree in Business Administration from the University of Iowa and a bachelor of science degree in Mathematics, Computer Science and Business Administration from Coe College. -
31
3:32
Marius Moscovici interviewed at Strata Rx
by OreillyMedia 51 views
Marius Moscovici (Metric Insights)
-
32
2:07
Karen Farrell interviewed at Strata Rx
by OreillyMedia 76 views
Karen Farrell ( Nuance Communications, Inc.)
-
33
3:15
